The FDA has granted breakthrough therapy designation to ficerafusp alfa with Keytruda for some patients with head and neck squamous cell carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback